SCHEMBL25262103

SCHEMBL25262103

O=C(O)Nc1cc(F)cc(Br)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP1 P24666 2/20 0.41
EGFR P00533 1/20 0.40
BCHE P06276 1/20 0.37
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
HPGD P15428 2/20 0.36
POLB P06746 1/20 0.36
ALDH1A1 P00352 2/20 0.36
P2RX1 P51575 1/20 0.36
P2RX4 Q99571 1/20 0.36
P2RX7 Q99572 1/20 0.36
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
GRM4 Q14833 1/20 0.36
MAPK14 Q16539 1/20 0.36
GPR35 Q9HC97 1/20 0.35
GFER P55789 1/20 0.35
ATM Q13315 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19813825 0.85 ACP1 (0.47) ACP1MEN1KMT2APOLBMAPK14
SCHEMBL15397572 0.85 ACP1 (0.52) ACP1MEN1KMT2APOLBMAPK14
SCHEMBL2093377 0.85 EGFR (0.50) EGFRNPC1RAB9AMEN1KMT2A
SCHEMBL29556931 0.84 MAPK14 (0.43) ACP1EGFRNPC1RAB9AMEN1
SCHEMBL20560189 0.82 ACP1 (0.40) ACP1EGFRBCHENPC1RAB9A
SCHEMBL707356 0.82 LMNA (0.48) ACP1RAB9AMEN1KMT2APOLB
SCHEMBL26606902 0.82 ACP1 (0.47) ACP1BCHENPC1RAB9AMEN1
SCHEMBL30573043 0.82 ACP1 (0.47) ACP1BCHENPC1RAB9AMEN1
SCHEMBL29555834 0.80 MAPK14 (0.46) ACP1EGFRNPC1RAB9AMEN1
SCHEMBL29418058 0.79 SMN1; SMN2 (0.43) ACP1EGFRRAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024030000-A1 NOVEL COMPOUND AS HYPOXIA-INDUCIBLE FACTOR 1(HIF-1) INHIBITOR OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 주식회사 넥스트젠바이오사이언스 2024-02-08 WO disclosed
US-20230278984-A1 UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS GLOBAL BLOOD THERAPEUTICS INC (US) 2023-09-07 US disclosed
EP-4188542-A1 UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS Global Blood Therapeutics, Inc. (US) 2023-06-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278984-A1 UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS PKM, PDK1, PDK2 ACP1 2827/4885EGFR 4492/4885BCHE 4139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.